Exclusive Summary

• - FDA-approved ANDA (#215215) with US-FDA GMP and US registration enables strong reference for multi-region tenders and filings
• - A bactericidal, once-daily anti-MRSA agent for SAB/right-sided endocarditis and cSSTI, with clear guideline endorsement as a key alternative to vancomycin
• - Sustained global burden of MRSA and VRE: SAB incidence ~10–30 per 100,000 in high-income countries with 15–30% mortality drives steady hospital demand
• - Despite crowded generics, US approval and reliable supply create a composite edge across price, compliance, and availability in hospital tenders
• - Versus originator pricing, generics typically cut costs by 70–90%, bringing 500 mg vial therapy to a far lower daily cost and enabling rapid uptake